Shimadzu (Asia Pacific) & Changi General Hospital (CGH) Renew Another 3-Year Collaboration Agreement during Signing Ceremony at CGH Simei Campus
The Signing of the Research Collaboration Agreement between Shimadzu (Asia Pacific) and Changi General Hospital
Shimadzu (Asia Pacific) and Changi General Hospital (CGH) recently reaffirmed their commitment to Advanced Healthcare by renewing their partnership through another 3-year Research Collaboration Agreement. The agreement was signed by Clinical Associate Professor Ng Kee Chong, CGH Chief Executive Officer and Mr Prem Anand, Shimadzu (Asia Pacific) Managing Director at CGH Simei Campus on 27 May 2024, and witnessed by Adj Associate Professor Siau Chuin, CGH Chairman, Medical Board and Mr Umeda Mitsuru, Shimadzu (Asia Pacific) Senior General Manager, MSD. This marks the continuation of the public-private partnered Clinomics Laboratory, the Shimadzu-CGH Clinomics Centre (SC3).
Accelerating Healthcare Advancements: The Remarkable Progress of SC3
The establishment of the SC3 in 2021 brings together the clinical and research expertise of CGH with Shimadzu’s diagnostic and analytical capabilities to contribute to enhanced medical care and treatment of hypertension in Singapore. With its development into a full-fledged clinical service provider in 2023, SC3 allows for the testing of hypertensive patients’ blood to be processed locally, significantly reducing turnaround times and resulting in an overall enhanced patient journey. The clinical service has since been expanded to other hospitals in Singapore. As a regional reference centre for mass spectrometry-based clinical tests, SC3 also aims to extend its reach in the Asia Pacific region.
SC3 is pioneering the application of liquid chromatography using Shimadzu’s artificial intelligence (AI)-assisted mass spectrometry to enhance clinical diagnosis. In the current AI-driven era where the world increasingly relies on smart technologies to assist with everyday tasks, Analytical Intelligence has become particularly relevant to maximize the accuracy and repeatability of liquid chromatography (LC) analysis. SC3 is equipped with mass spectrometers that enable more specimens to be analysed in a shorter time.
Driving Precision Medicine
The integration of liquid chromatography, mass spectrometry, and AI represents a paradigm shift in the field of diagnostics. These advanced technologies provide a more nuanced understanding of hypertension, enabling clinicians to analyse complex data and identify key biomarkers with precision, such as the two hormones – aldosterone and renin. This is due to the higher analytical specificity and sensitivity compared to the traditional methodologies, which play a crucial role in distinguishing between two specific types of hypertension: salt-sensitive hypertension and primary aldosteronism, which is a relatively lesser-known but curable form of hypertension. This ultimately paves the way for quicker, more accurate test results, and thus improved patient outcomes.
Embracing Future Horizons: SC3 Vision for Advanced Healthcare
The signing ceremony to mark the continual collaboration on the Shimadzu-CGH Clinomics Centre (SC3) was held at the CGH Simei Campus on 27 May 2024
With the renewed collaboration between Shimadzu and CGH, SC3 will continue to develop its capabilities to test for adherence for a wider range of medications, catering to a wider range of patients and allowing for tailored dosage and treatment plans in order to prioritise the highest efficacy.
As SC3 embraces the future horizons, Shimadzu will continue to provide support through providing cutting-edge innovations. As the only technology company in the world with synergistic innovations between Analytical Instruments and Medical Systems, Shimadzu is dedicated to advancing AI-driven solutions to improve healthcare for the patients.
Through its continuous expansion, SC3 is set to transform the healthcare landscape of the Asia Pacific region. The renewal of the SC3 agreement solidifies the commitment of both Shimadzu (Asia Pacific) and CGH to advancing healthcare through the use of innovative analytical and medical technologies. This partnership is a testament to the power of collaboration in creating synergistic solutions for Advanced Healthcare.